Amgen Astellas launches Repatha in Japan

25 April 2016

Japan-based Amgen Astellas BioPharma and Astellas Pharma (TYO: 4503) say that their proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha (evolocumab [genetically recombination] Injection) Syringe has become available in the Japanese market.

Repatha was developed in Japan by joint venture Amgen Astellas and US biotech major Amgen (Nasdaq: AMGN) and was approved by the Ministry of Health, Labor and Welfare earlier this year (The Pharma Letter January 23). Amgen Astellas and Astellas will co-promote Repatha in Japan.

Repatha is indicated for the treatment of patients with familial hypercholesterolemia (FH) or hypercholesterolemia who have high risk of cardiovascular events and do not adequately respond to HMG-CoA reductase inhibitors (statins).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK